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Abstract 
 
Purpose: To determine the implications of the use of the Anisotropic Analytical Algorithm 
(AAA) for the production and dosimetric verification of IMRT plans for treatments of the 
prostate, parotid, nasopharynx and lung. 
Methods: 72 IMRT treatment plans produced using the Pencil Beam Convolution (PBC) 
algorithm were recalculated using the AAA and the dose distributions compared. 24 of the 
plans were delivered to inhomogeneous phantoms and verification measurements made 
using a pinpoint ionisation chamber. The agreement between the AAA and measurement 
was determined.  
Results: Small differences were seen in the prostate plans, with the AAA predicting slightly 
lower minimum PTV doses. In the parotid plans, there were small increases in the lens and 
contralateral parotid doses while the nasopharyngeal plans revealed a reduction in the 
volume of the PTV covered by the 95% isodose (the V95%) when the AAA was used. Large 
changes were seen in the lung plans, the AAA predicting reductions in the minimum PTV 
dose and large reductions in the V95%. The AAA also predicted small increases in the mean 
dose to the normal lung and the V20. In the verification measurements, all AAA calculations 
were within 3% or 3.5mm distance to agreement of the measured doses.  
Conclusions: The AAA should be used in preference to the PBC algorithm for treatments 
involving low density tissue but this may necessitate re-evaluation of plan acceptability 
criteria. Improvements to the Multi-Resolution Dose Calculation algorithm used in the inverse 
planning are required to reduce the convergence error in the presence of lung tissue. There 
was excellent agreement between the AAA and verification measurements for all sites.  
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Introduction 
 
An acknowledged limitation of the correction-based commercial treatment planning system 
(TPS) dose calculation algorithms in wide use today is a limited ability to account for the 
effects of electron transport [1]. Significant errors in the calculated dose distributions often 
result from such algorithms poor modelling of situations in which electronic equilibrium does 
not exist, in particular in the presence of inhomogeneities [2,3,4]  or when small fields are 
used [5,6]. More recently, the introduction of convolution-superposition (CS) algorithms that 
better account for electron transport has enabled improved estimation of dose distributions, 
particularly in the absence of electronic equilibrium.  
 
The Anisotropic Analytical Algorithm (AAA) [7], implemented in the Eclipse TPS (Varian 
Medical Systems, Palo Alto, Ca), is one such convolution-superposition algorithm. In 
common with the older photon algorithm in Eclipse, the Pencil Beam Convolution (PBC) 
algorithm, it considers the dose around narrow pencil beams, although the implementation is 
quite different. The PBC algorithm calculates the dose by convolution of a field intensity 
fluence with the kernel that describes dose deposition around the primary photon pencil 
beam in water. Inhomogeneities are accounted for by the subsequent application of 
corrections such as the Equivalent Tissue-Air Ratio (ETAR) correction, in which the radius of 
the field and the depth are scaled according to the density of the media.  
 
By contrast, the pencil beams in the AAA include separately-modelled contributions from 
three sources  primary photons, extra-focal photons and contaminating electrons. Each 
source has associated with it a fluence, an energy deposition density function and a scatter 
kernel. Consideration of inhomogeneities is more intrinsic in the AAA; the scatter kernels that 
model lateral energy scattering are scaled anisotropically according to electron density, while 
the energy deposition density functions undergo density scaling in the direction of the pencil 
beams. The total energy deposited by each pencil beam is obtained by the convolution of 
the contributions from the three sources and the final dose is calculated by the superposition 
of the contributions from the pencil beams.  
 
The improved accuracy of the AAA in phantom situations and 3D conformal radiotherapy 
(3D-CRT) treatment plans compared to Eclipses Pencil Beam Convolution (PBC) algorithm 
(the Eclipse implementation of the Single Pencil Beam algorithm of the same manufacturers 
CadPlan TPS) has been reported by several authors [8-12].  
 
Intensity-modulated radiotherapy (IMRT) fields, which often comprise large numbers of small 
beam segments, place particular importance on the accurate modelling of small fields. 
Several investigations into the accuracy of a number of CS algorithms in IMRT planning [13-
16] have been reported. However, there can be large differences in the abilities of different 
CS algorithms to model the effects of factors such as small fields and inhomogeneities [17] 
and so the accuracy of the AAA in calculating IMRT dose distributions cannot be inferred 
from the performance of other algorithms.  
 
Sterpin et al. [18] compared dose distributions calculated by the AAA and Monte Carlo 
simulation, the current gold standard for dose calculation, in a phantom and for four 
treatment plans and found good agreement between the two, albeit with localised 
exceptions. They further concluded that the AAA generally provided significant 
improvements over the PBC algorithm.  
 
The aim of this work was to investigate the clinical implications for IMRT treatment planning 
of changing from a correction-based, pencil beam dose calculation model to the AAA.  
 
Materials and Methods 
 
Treatment Planning 
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Twenty prostate treatment plans were produced, using a fixed beam arrangement with fields 
at gantry angles 180, 100, 45, 315 and 260 (IEC1217). The prescribed dose was 60Gy 
in 20 fractions. The organs at risk (OARs) considered in the inverse planning process were 
the rectum, the bladder and the femoral heads. The tolerance doses were for no more than 
50% of the bladder or rectum to receive 57Gy and no more than 2.0cm3 of the femoral heads 
to receive 55Gy.  
 
Eighteen head and neck plans were produced, nine for the treatment of parotid tumours and 
nine for nasopharyngeal tumours. The parotid plans, for which the prescription dose was 
60Gy in 30 fractions used the five-field class solution developed in a previous study [21]. The 
OARs for which dose-volume constraints were specified in the inverse planning were the 
brain, spinal cord, contralateral parotid and lenses. The tolerance for the contralateral parotid 
was a mean dose of 26Gy [22,23]. The prescription doses for the nasopharyngeal plans 
were 50.4Gy in 1.8Gy fractions (one patient), 60Gy in 2Gy fractions (four patients) or 70Gy 
in 2Gy fractions (four patients). All plans used five fields, although the gantry angles used 
and the considered OARs varied according to the size and location of the PTV. The 
tolerance doses used were: brainstem and spinal cord 44Gy, brain no more than 10% 
receiving 55Gy, optic nerves and chiasm 50Gy and lenses 4Gy. 
 
Finally, thirty-six non-small cell lung cancer (NSCLC) treatment plans were produced using 
the CHART fractionation (54Gy in 36 fractions). As the PTV locations varied widely, the 
beam angles were optimised for each patient. Two plans required seven fields to produce 
acceptable dose distributions; all others used five fields. The inverse planning aimed to 
maximise PTV coverage while minimising the dose received by lung tissue outside the PTV 
and not exceeding the tolerance dose of 44Gy for the spinal cord used clinically at this 
centre.  
 
All dMLC IMRT treatment plans were produced using Eclipse, with version 7.5.18 of the 
Dose Calculation Server. Inverse planning was performed with the Dose-Volume Optimiser 
(DVO) algorithm, which employs a convolution-superposition algorithm, the Multi-Resolution 
Dose Calculation (MRDC) algorithm, to estimate the dose following each iteration of the 
optimisation process. The aim of the inverse planning was to meet the recommendations in 
ICRU Report 62 [24] for target coverage of between 95% and 107% of the prescription dose 
while minimising the doses to the OARs. (The PTV constraints set at the start of each 
optimisation were tighter than this, as has been found to be necessary with the DVO in order 
to encourage conformation to the ICRU recommendations. Constraints were interactively 
adjusted during each optimisation as required in order to improve the final distribution.) 
 
The final, forward dose calculations were performed using the PBC algorithm with ETAR 
inhomogeneity correction and subsequently with the AAA with inhomogeneity correction, 
using a 2.5mm calculation grid. The choice of algorithm influenced only the forward dose 
calculation from the pre-determined MLC leaf movements. Each PBC plan was normalised 
such that the mean dose to the PTV was equal to the prescription dose; the same monitor 
units were set for the corresponding AAA plan.  
 
The quality of each treatment plan was analysed with regard to its clinical acceptability. Any 
implications for treatment planning practice of the choice of algorithm were considered. 
Dose-Volume Histograms (DVHs) were produced for all plans and from them, the doses to 
the PTV and OARs were analysed. 
 
PTV doses were compared in terms of the minimum and maximum doses and the 
percentage volume of the PTV receiving a dose greater than 95% of the prescription dose, 
V95%. Clinically-relevant OAR dose parameters were compared. For the prostate plans, these 
were the maximum bladder, rectum and femoral head doses, as well as the percentage 
volume of the bladder and rectum receiving 80% of the prescription dose (V80%). For the 
NSCLC plans, the maximum dose to the spinal cord as well as the mean dose to the non-
GTV lung (hereafter referred to as normal lung) and the percentage volume of the normal 
lung receiving at least 20Gy (V20) [25] were considered. For the parotid plans, the 
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parameters compared were the maximum brain, spinal cord and lens doses and the mean 
dose to the contralateral parotid gland. For the nasopharyngeal plans, there was some 
variation in the involved OARs between patients. The parameters studied were the 
maximum spinal cord dose for all patients and, where involved, the maximum brain, lens, 
optic nerve and optic chiasm doses. 
 
In addition, a Conformity Index (CI) [26] was used to quantify the degree to which the high 
dose region was conformed to the PTV. The CI takes both the volume of PTV and the 
volume of normal tissue receiving at least 95% of the prescription dose into account and was 
calculated as the product of two parameters. The first parameter was the fraction of the PTV 
that received at least 95% of the prescription dose level, (VPTV95 / VPTV). The second 
parameter was the ratio of VPTV95 to the total volume of tissue receiving at least 95% of the 
prescription dose (that is, the treated volume, VT). Therefore, the CI was calculated as 
follows: 
T
PTV
PTV
PTV
V
V
V
VCI 9595  
A CI equal to unity indicates exact conformation of the 95% isodose to the PTV, with no 
tissue outside the PTV receiving this dose, while a CI of zero indicates a geographical miss.  
 
The statistical significance of differences between the dose parameters from the two 
algorithms was calculated using a paired, two-tailed Students t-test. 
 
Verification 
The accuracy of the dose distributions calculated by the AAA in terms of their agreement 
with in-phantom verification measurements as typically performed prior to IMRT treatments 
[19,20] was assessed.  
 
Ten prostate plans and six plans from each of the parotid, nasopharynx and lung plans were 
randomly chosen and transferred as verification plans, using the same dMLC files and 
monitor units, to CT scans (with a slice spacing of 2.5mm) of one of three semi-
anthropomorphic phantoms. The phantoms (all CIRS Inc., Norfolk, VA) were a pelvic 
phantom containing bone-equivalent inhomogeneities (relative electron density 1.506), a 
head and neck phantom containing bone inhomogeneities and air gaps and a thorax 
phantom containing bone-equivalent and lung-equivalent (relative electron density 0.207) 
inhomogeneities. The dose distribution from each plan was calculated using the AAA with 
inhomogeneity correction and 2.5mm grid spacing. The plans were transferred to a Varian 
600C linear accelerator, equipped with a 120-leaf Millennium MLC at 6MV, via the Varis 
record and verify system (Varian Medical Systems, Palo Alto, Ca).  
 
The doses at a selection of reference points within the phantoms were measured using a 
PTW model 31016 (0.016cc) pinpoint ionisation chamber (PTW-Freiburg, Freiburg, 
Germany) and PTW Unidos Universal electrometer, correcting for linear accelerator output. 
Between three and six points were used for each plan, as shown in Table 2. The measured 
doses were compared to those calculated by the AAA. In instances where the discrepancy 
between measurement and calculation exceeded 3%, the distance to agreement between 
the measured and calculated doses was determined on Eclipse by measuring the distance 
between the measurement point and the isodose corresponding to dose measured at that 
point.  
 
Results 
Treatment Planning 
Example DVHs for a prostate plan, a nasopharynx plan and a lung plan are shown in Figure 
1. The results of the comparison of the IMRT treatment plans as calculated by the two 
algorithms are shown in Table 1.  
 
In the prostate plans, the AAA predicted lower doses than the PBC algorithm, including 
slightly lower coverage by the 95% isodose. However, of those differences that were 
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statistically significant, only the reduction of 0.6% in the minimum PTV dose was of any 
clinical significance. A similar pattern was seen in the parotid plans, the only significant 
differences between the algorithms being the increases in the contralateral parotid and lens 
doses, although these were of limited clinical significance.   
 
The PTV dose distributions in the nasopharyngeal plans were generally less ideal than in 
either the parotid or prostate plans, with much higher inter-patient variability in the maximum 
and minimum PTV doses and significantly poorer coverage of the target. The AAA predicted 
a slightly lower maximum dose to the brain but, more crucially, a reduction of approximately 
5% of the PTV receiving 95% of the prescription dose. The lens doses from both algorithms 
were high as a result of a clinical decision to compromise them to avoid further reductions in 
target coverage.  
 
The lung plans showed a markedly different pattern. The AAA predicted slightly lower 
minimum PTV doses, and a reduction of 9% of the volume of the PTV covered by the 95% 
isodose. Changes in the spinal cord and lung doses were smaller and of limited clinical 
significance. The poorer coverage of the PTV was reflected in the conformity index, which 
was significantly lower when the AAA was used to calculate the dose distribution.  
 
Verification 
The results of the phantom verification measurements are shown in Table 2. The 
reproducibility of the measurements was estimated by performing the measurements for the 
first plan of each treatment site five times, setting the equipment up anew between 
measurements and was found to be 0.3% for the measurements in the thorax and head and 
neck phantom and 0.5% in the pelvic phantom.  
 
The agreement between measurement and calculation for the prostate and head and neck 
plans was excellent, with no discrepancy exceeding 3% or (in regions of high dose gradient) 
1.6mm distance to dose agreement. The agreement for the lung and nasopharynx plans was 
slightly worse, the maximum discrepancies being 3% or 3.5mm (but for both sites, a single 
point was outside 3% or 3mm).  
 
The AAA tended to overestimate the doses at the measurement points, the mean 
discrepancy over all measurements being 1.0%. The measurements in the lung-equivalent 
region of the thorax phantom showed small mean underestimates. However, the inter-patient 
variability in the discrepancies limit the conclusions that can be drawn from these 
observations.  
 
Discussion 
If the AAA is taken to provide a more accurate representation of the dose distribution from a 
given treatment, the comparisons between the AAA and PBC dose distributions in Table 1 
provide an indication of the difference between the dose predicted by the PBC algorithm and 
that actually delivered.  
 
In the prostate plans, the distributions were found to be very similar, with no differences 
between the OAR doses that were considered clinically significant. In all but three patients, 
the AAA predicted a lower minimum PTV dose than the PBC, with a mean reduction of 0.6% 
of the prescription dose. However, the two algorithms predicted virtually identical values of 
V95% and the mean value of the minimum PTV dose was above the ICRU-recommended 
level of 95% (only four patients falling below this value). The parotid plans showed even 
greater agreement between the algorithms than the prostate plans, with no clinically 
significant differences.  
 
That the differences between the algorithms dose distributions for these plans were so small 
was largely due to two factors. Firstly, the beams used for these plans were such that there 
was little involvement of heterogeneities. The prostate fields were angled such that they 
avoided most of the bony anatomy of the pelvic region, while only two of the parotid beams 
passed through inhomogeneities, one of them being the field contralateral to the PTV whose 
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typical contribution to the total PTV dose was proportionately lower than the other fields. As 
a result, the effects of the two algorithms abilities to account for inhomogeneities on the final 
dose distribution was restricted. Secondly, as each fields fluence exhibited a relatively low 
level of intensity modulation, each largely comprised a single MLC opening whose size 
evolved but had an equivalent square size of between 5 and 10cm for all but the first and 
last few seconds of the delivery. (This is broadly analogous to the use of a small number of 
large beam segments rather than a very high number of much smaller segments in a 
multiple static segments delivery.) Therefore, as the open part of the field at any time during 
the delivery was relatively large, any differences in the algorithms ability to handle small field 
segments did not have a large influence on the dose distributions. 
 
The lenses and femoral heads were outside the main fields in most instances. Therefore, the 
differences in the doses to those structures, in the most part, resulted from differences in the 
modelling of the transmission through the MLC and of the dose beyond the penumbra. The 
higher doses outside the field seen with the AAA are consistent with those reported for open 
fields by Fogliata et al. [8].  
 
The verification measurements on the pelvic phantom demonstrated the accuracy of the 
AAA. The mean discrepancies between the calculated and measured doses at all 
measurement points were no greater than 1.2%. The discrepancies for several individual 
measurements were somewhat higher, up to 6.3%, whenever the dose discrepancy 
exceeded 3%, the measurement point was in a high dose gradient and the distance to dose 
agreement was no greater than 1.2mm. The agreement between the AAA and measurement 
for the parotid plans was similarly to within 3% or 1.1mm distance to agreement. The larger 
mean discrepancy seen at the Anterior point was again the result of the points location in a 
high dose gradient for most of the plans; all measurements here were within 2.5% or 1.1mm 
distance to agreement.  
 
The close proximity of OARs to the PTVs (as well as the considerably greater size of the 
PTVs) in the nasopharyngeal plans led to less uniform field fluences than in the parotid plans 
and necessitated compromises in the PTV and/or OAR doses in some patients. This was 
reflected in the plans PTV coverage and the higher inter-patient variations based on the 
PBC-calculated distributions in many of the dose parameters studied. In some plans, clinical 
decisions were made to exceed OAR tolerances (most commonly with the lenses or where 
OARs lay within the PTV) rather than further compromise the PTV coverage. In only one of 
these patients did using the AAA cause an OAR (a lens) whose maximum dose was within 
tolerance according to the PBC algorithm to rise above tolerance and in no instance was the 
difference between the two algorithms large enough that a different decision would have 
been made on the basis of the AAA-calculated distribution.  
 
The less uniform fluences in these plans than were required for the prostate and parotid 
plans resulted in a reduction in the size of the MLC openings throughout the field deliveries. 
The agreement between the doses calculated by the AAA plans and measurement on the 
head and neck phantom was less good for these nasopharynx plans. The highest 
discrepancies were seen at the Posterior point, outside the high dose region, although all 
measurements there agreed with the AAA doses to within 2.1% or 1.3mm distance to 
agreement. Only for one measurement (at the Right measurement point) did the level of 
agreement exceed 3% or 3mm, a commonly-used action level for IMRT verification [20,27]. 
The agreement between the AAA and measurement was comparable to that reported 
between other CS algorithms and measurement or Monte Carlo simulation [13-16].  
 
Similar levels of agreement were seen for the lung plans, measured on the thorax phantom. 
All calculated doses agreed with measurement to within 3% or 3.3mm distance to agreement 
and all but one to within 3% or 3mm, confirming the accuracy of the AAA calculations of 
these IMRT plans. The magnitudes of the mean discrepancies were of the same order as 
were found in a previous study for conventional radiotherapy treatment fields measured on 
the thorax phantom [9] and as those reported for IMRT fields by Khodri et al. [28].  
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In the lung plans, all the OAR dose parameters investigated were found to be higher when 
calculated with the AAA than had been predicted by the PBC algorithm. However, the 
differences were not clinically significant and it should be noted that even the AAA-calculated 
values remained within tolerance for every plan, with the single exception of one plans V20, 
which exceeded the tolerance of 35% even for the PBC algorithm. However, it was, perhaps, 
in the PTV coverage that the most significant issues arose.  
 
The ICRU recommendations state that the dose to the PTV should lie within 95% to 107% of 
the prescription dose. There was no significant difference in the maximum PTV dose when 
the plans were recalculated with the AAA. However, there was a large mean reduction in the 
minimum PTV dose of 4% and a reduction of 9% in the volume of the PTV covered by the 
95% isodose. These  as with the increase in lung dose and deterioration in the conformity  
were the result of the broadening of the penumbra caused by the AAAs improved modelling 
of the lateral electron transport and was worse for those patients whose PTV contained a 
large amount of lung tissue, such as the example shown in Figure 2.  
 
There are clear discrepancies between the final PTV DVH predicted by the MRDC at the end 
of the inverse planning and that from the AAA, suggesting that the convolution-
superposition-based MRDC is insufficiently capable of predicting the effects of low density 
tissue with sufficient accuracy to fully enable accurate convergence to the required dose 
constraints. The production of IMRT plans within the ICRU recommended PTV dose limits 
for the lung region, at least using the standard inverse planning methods employed in this 
work, is unlikely to be a realistic possibility. This raises the issue of whether the prescribed 
dose should be adjusted in light of the improved knowledge of the delivered distribution.  
 
On one hand, it could be argued that the PTV coverage being lower than originally thought 
might necessitate an increase in the prescribed dose in order to ensure that the PTV is 
covered to the extent that the PBC algorithm predicted. This would be very much dependent 
upon the acceptance criteria used in treatment plan evaluation. For example, if the 
requirement were for the mean PTV dose to be equal to the prescription dose, the required 
increase in the instances studied here would not be large. The mean MU would be increased 
by 1.3% for the nasopharyngeal plans and by less than 1% for the other sites. Table 3 
shows the corresponding dose parameters following renormalisation of the AAA plans such 
that the mean PTV dose was equal to the prescription dose (while the mean changes in 
monitor units involved in the renormalisation for each site are shown in Table 4). As can be 
seen, the differences between the original AAA plans and the renormalised plans small and 
so the implications of such a change would be limited. However, clinically significant 
reductions in PTV coverage in the NSCLC plans remain. To alter the AAA plans such that an 
equivalent degree of coverage, for example, in terms of the fraction of the PTV covered by 
the 95% isodose, were achieved would require much larger increases in monitor units.  
 
On the other, current clinical experience of treatment outcomes are correlated with the doses 
as predicted by less accurate algorithms. To alter treatment regimes solely on the basis of 
improved dose calculation accuracy would have wide ranging implications particularly in 
terms of normal tissue reactions. The treatment of NSCLC by radiotherapy has higher 
associated uncertainties than most radiotherapy treatments, due to factors such as the 
particularly significant tumour motion and poor prognoses of patients; to increase doses 
purely on the basis of improved knowledge of the dose distributions would be to introduce a 
further source of uncertainty into the radiotherapy process. Of paramount importance in 
making the clinical decision as to whether a treatment regime should be so altered is the 
development of more accurate dose-effect relationships than are currently available; the 
more accurate knowledge of the doses afforded by improved calculation algorithms is vital to 
this end. 
 
Conclusions 
The AAA was, in general, not found to significantly alter the quality of IMRT treatment plans 
for the prostate, parotid or nasopharynx compared to the PBC algorithm. However, some 
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small differences were seen and the importance of evaluating treatment plans on an 
individual basis cannot be overemphasised. The PBC algorithm overestimated the PTV 
coverage in IMRT plans for NSCLC, the AAAs more accurate modelling of lateral electron 
transport demonstrating significant increases in the volume of the PTV being underdosed. 
The use of the AAA in preference to the PBC algorithm for treating planning in which low 
density tissue such as lung is present is recommended, although improvements to the 
MRDC algorithm are required for IMRT treatments to benefit fully from its improved 
accuracy. The differences between the algorithms were of similar magnitude to those 
previously found for conventional plans.  Excellent agreement between the AAA and 
verification measurements using a pinpoint ionisation chamber in inhomogeneous phantoms 
was seen, the majority of calculated doses agreeing with measurement to within 3% or 3mm 
distance to agreement.  
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Fig. 1 Example DVHs for (top) a prostate plan, (middle) a nasopharynx plan and (bottom) a 
lung plan. The solid lines are the curves calculated by the PBC algorithm and the 
dashed lines are those calculated by the AAA 
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Fig. 2 An axial slice showing a representative comparison between the AAA and PBC 
algorithm distributions. The PTV is shaded. The isodoses displayed are 100%, 95%, 
90%, 80%, 50% and 20%. The broadening of the penumbra can be seen, particularly 
to the lateral side of the PTV.  
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Table 1 Summary of differences between the treatment plan parameters from the two 
algorithms 
 
Site Volume  Parameter  AAA  PBC  p 
     Mean SD  Mean SD   
Prostate PTV  Dmin (%)  95.5 1.8  96.1 2.0  0.001 
   Dmax (%)  100.9 1.0  101.9 0.7  0.000 
   V95% (%)  99.9 0.3  100.0 0.1  0.28 
            
 Rectum  Dmax (Gy)  58.3 0.9  58.8 0.9  0.000 
   V80% (%)  25.1 11.1  25.8 11.1  0.010 
            
 Bladder  Dmax (Gy)  59.7 0.4  60.1 0.3  0.000 
   V80% (%)  16.6 7.0  16.7 7.0  0.019 
            
 Femoral heads  Dmax (Gy)  37.2 5.4  37.0 5.5  0.000 
            
   CI  0.63 0.05  0.60 0.05  0.000 
            Parotid PTV  Dmin (%)  85.2 3.6  84.2 4.9  0.30 
   Dmax (%)  103.6 1.7  103.6 1.3  0.91 
   V95% (%)  98.0 1.0  98.5 1.0  0.13 
            
 Spinal Cord  Dmax (Gy)  40.8 4.2  41.0 4.3  0.52 
            
 Brain  Dmax (Gy)  28.1 6.1  28.0 6.2  0.46 
            
 C/L Parotid  Dmean (Gy)  16.5 1.4  15.8 1.4  0.000 
            
 Lenses  Dmax (Gy)  2.0 0.7  1.0 0.3  0.000 
            
   CI  0.80 0.05  0.79 0.07  0.20 
            Nasopharynx PTV  Dmin (%)  56.3 17.7  55.2 21.0  0.71 
   Dmax (%)  109.2 2.4  110.2 2.8  0.05 
   V95% (%)  77.8 22.9  82.5 23.3  0.015 
            
 Spinal Cord  Dmax (Gy)  35.7 14.1  36.1 14.4  0.15 
            
 Brain  Dmax (Gy)  52.6 9.5  53.5 9.8  0.038 
            
 Chiasm  Dmax (Gy)  43.5 16.8  44.3 17.3  0.06 
            
 Optic Nerves  Dmax (Gy)  50.7 7.4  51.0 6.4  0.67 
            
 Lenses  Dmax (Gy)  12.7 11.2  10.3 11.3  0.000 
            
   CI  0.68 0.19  0.69 0.19  0.41 
            Lung PTV  Dmin (%)  74.8 5.2  78.8 5.8  0.000 
   Dmax (%)  108.2 3.3  108.3 3.6  0.99 
   V95% (%)  88.2 5.6  97.2 2.0  0.000 
            
 Spinal Cord  Dmax (Gy)  36.4 8.5  35.6 8.1  0.000 
            
 Normal Lung  Dmean (Gy)  12.4 3.7  12.1 3.6  0.000 
   V20 (%)  23.2 8.5  22.7 8.3  0.001 
            
   CI  0.67 0.06  0.83 0.09  0.000 
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Table 2 Summary of the IMRT verification measurements for the four treatment sites 
 
Site Measurement 
Point 
Discrepancy 
(AAA  measured) / % 
 Comments 
  Mean SD   
Prostate Isocentre 0.0 0.7  All measurements within 3% or  
 Ant 1.2 0.8  1.6mm distance to agreement 
 Post 1.0 2.3   
 Right 1.2 1.1   
 Left 0.7 0.6   
      
Parotid Isocentre 0.9 0.6  All measurements within 3% or 
 Ant -1.9 3.6  1.1mm distance to agreement 
 Post 1.1 2.3   
      
Nasopharynx Isocentre 1.8 3.2  All measurements within 3% or 
 Right 2.0 2.9  3.5mm distance to agreement 
 Left -0.4 2.8   
 Post 3.6 6.8   
      
Lung Mediastinal_1 2.2 1.9  All measurements within 3% or 
 Mediastinal_2 2.0 1.4  3.3mm distance to agreement 
 Mediastinal_3 1.7 1.2   
 Mid Left Lung -0.9 3.7   
 Post Left Lung -0.6 3.0   
 Spinal Cord 2.6 2.7   
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Table 3 Summary of differences between the treatment plan parameters from the two 
algorithms after renormalisation of the AAA plans 
 
Site Volume  Parameter  AAA  PBC  p 
     Mean SD  Mean SD   
Prostate PTV  Dmin (%)  96.2 1.8  96.1 2.0  0.36 
   Dmax (%)  101.6 0.8  101.9 0.7  0.001 
   V95% (%)  100.0 0.2  100.0 0.1  0.34 
            
 Rectum  Dmax (Gy)  58.8 0.9  58.8 0.9  0.69 
   V80% (%)  26.4 11.2  25.8 11.1  0.003 
            
 Bladder  Dmax (Gy)  60.2 0.3  60.1 0.3  0.22 
   V80% (%)  17.0 7.1  16.7 7.0  0.000 
            
 Femoral heads  Dmax (Gy)  37.4 5.4  37.0 5.5  0.000 
            
   CI  0.59 0.06  0.60 0.05  0.34 
            Parotid PTV  Dmin (%)  85.8 3.8  84.2 4.9  0.09 
   Dmax (%)  104.3 1.4  103.6 1.3  0.15 
   V95% (%)  98.7 0.7  98.5 1.0  0.47 
            
 Spinal Cord  Dmax (Gy)  41.0 4.1  41.0 4.3  0.84 
            
 Brain  Dmax (Gy)  28.3 6.1  28.0 6.2  0.015 
            
 C/L Parotid  Dmean (Gy)  16.6 1.4  15.8 1.4  0.000 
            
 Lenses  Dmax (Gy)  2.0 0.7  1.0 0.3  0.000 
            
   CI  0.79 0.06  0.79 0.07  0.29 
            Nasopharynx PTV  Dmin (%)  57.2 18.2  55.2 21.0  0.48 
   Dmax (%)  110.7 1.8  110.2 2.8  0.27 
   V95% (%)  83.0 20.3  82.5 23.3  0.71 
            
 Spinal Cord  Dmax (Gy)  36.3 14.4  36.1 14.4  0.48 
            
 Brain  Dmax (Gy)  53.3 9.4  53.5 9.8  0.57 
            
 Chiasm  Dmax (Gy)  44.1 17.0  44.3 17.3  0.52 
            
 Optic Nerves  Dmax (Gy)  51.5 7.5  51.0 6.4  0.48 
            
 Lenses  Dmax (Gy)  12.8 11.2  10.3 11.3  0.000 
            
   CI  0.70 0.16  0.69 0.19  0.76 
            Lung PTV  Dmin (%)  75.5 5.8  78.8 5.8  0.000 
   Dmax (%)  108.6 2.6  108.3 3.6  0.30 
   V95% (%)  90.0 2.7  97.2 2.0  0.000 
            
 Spinal Cord  Dmax (Gy)  36.4 8.2  35.6 8.1  0.000 
            
 Normal Lung  Dmean (Gy)  12.4 3.6  12.1 3.6  0.000 
   V20 (%)  23.2 8.3  22.7 8.3  0.000 
            
   CI  0.77 0.08  0.83 0.09  0.000 
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Table 4 Summary of the monitor unit (MU) changes resulting from renormalisation of 
the AAA plans. Positive values indicate increased MU after renormalisation, 
expressed as a percentage of the PBC-calculated MU. 
 
Site MU (%) p 
 Mean SD  
Prostate 0.8 0.5 0.000 
Parotid 0.7 0.7 0.02 
Nasopharynx 1.3 0.8 0.002 
Lung 0.4 1.2 0.08 
 
 
